Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia.
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia.
复制标题
DOI：
10.1186/s13148-015-0151-8
复制
发表时间：
2015
影响因子：
5.7
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Zhang C;Zhong JF;Stucky A;Chen XL;Press MF;Zhang X
急性淋巴细胞白血病（ALL）通常被认为是一种具有高度增殖性恶性淋巴细胞的侵袭性肿瘤实体的遗传性疾病（病症）。然而，近年来，在阐明ALL相关过程方面取得了重大进展。因此，我们理解组蛋白乙酰化参与了控制ALL发育结果的基因表达的永久性变化。在这篇文章中，我们将重点关注组蛋白乙酰化与ALL，其作为预后生物标志物的意义，以及其临床前和临床应用。
Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their preclinical and clinical applications.